Agenus Inc. — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Agenus Inc. appears in 9 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials9

Recruiting shown2

Roles2

SourceClinicalTrials.gov

Clinical trials

9 shown

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerNCT05608044 · lead sponsor · 2022-11-30

ACTIVE_NOT_RECRUITING

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerNCT03860272 · lead sponsor · 2019-03-20

ACTIVE_NOT_RECRUITING

Study of AGEN1884 With Pembrolizumab in 1L NSCLCNCT03411473 · lead sponsor · 2017-10-04

Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung CancerNCT00098085 · lead sponsor · 2003-09-01

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory ApprovalNCT06751524 · lead sponsor

A Study of Evofosfamide in Combination with Zalifrelimab and BalstilimabNCT06782555 · collaborator · 2025-01-08

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast CancerNCT05318469 · collaborator · 2023-10-13

Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)NCT06322108 · collaborator · 2024-06-13

ACTIVE_NOT_RECRUITING

Combination Immunotherapy in Colorectal CancerNCT05571293 · collaborator · 2023-03-17

ACTIVE_NOT_RECRUITING

Sponsor roles

lead sponsor5

collaborator4

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.